Recently, new immune-based treatments have shown impressive results when multiple myeloma returns, changing how doctors treat patients early after relapse.
Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...
An immunotherapy kept multiple myeloma at bay for over 80 percent of patients in a three-year clinical trial, and the FDA ...
Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...
The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for ...
Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...
Real world data show multiple myeloma survival varies by treatment line and autologous stem cell transplant status. Read more ...
D-VRd is the only quadruplet regimen approved for patients with newly diagnosed multiple myeloma, irrespective of transplant ...
Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while ...
The FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), lenalidomide ...
How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...
The mother and daughter received identical diagnoses just over a year apart of multiple myeloma, a blood cancer that occurs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results